The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Open accessAbstract
The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging, treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage IV RCC typically undergo surgery and/or receive systemic therapy. Tumor histology and risk stratification of patients is important in therapy selection. The NCCN Guidelines for Kidney Cancer stratify treatment recommendations by histology; recommendations for first-line treatment of ccRCC are also stratified by risk group. To further guide management of advanced RCC, the NCCN Kidney Cancer Panel has categorized all systemic kidney cancer therapy regimens as “Preferred,” “Other Recommended Regimens,” or “Useful in Certain Circumstances.” This categorization provides guidance on treatment selection by considering the efficacy, safety, evidence, and other factors that play a role in treatment selection. These factors include pre-existing comorbidities, nature of the disease, and in some cases consideration of access to agents. This article summarizes surgical and systemic therapy recommendations for patients with relapsed or stage IV RCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21654 · Cited by 16,522
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Self-citationSunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
Self-citationSorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Self-citationNivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656 · cited 3×
“events after ipilimumab/nivolumab treatment received high-dose steroids.(46) Based on these data, the panel rec-”
InfluentialSelf-citationWilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
Self-citationPembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816714 · Cited by 3,403
Self-citationMotzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019
Self-citationYang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Motzer, R. J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M. T., Venugopal, B., Kollmannsberger, C., Negrier, S., Uemura, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816047 · Cited by 2,503
Self-citationSternberg, C. N., Davis, I. D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J., Barrios, C. H., Salman, P., Gladkov, O. A., Kavina, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9764 · Cited by 2,471
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Oudard, S., Negrier, S., Szczylik, C., Pili, R., Bjarnason, G. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1293 · Cited by 2,181
Self-citationHeng, D. Y. C., Xie, W., Regan, M. M., Warren, M. A., Golshayan, A. R., Sahi, C., Eigl, B. J., Ruether, J. D., Cheng, T., North, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4809 · Cited by 2,133
Self-citationPazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Cella, D., Reeves, J., Hawkins, R., Guo, J., Nathan, P., Staehler, M., de Souza, P., Merchan, J. R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303989 · Cited by 1,923
Self-citationRini, B. I., Escudier, B., Tomczak, P., Kaprin, A., Szczylik, C., Hutson, T. E., Michaelson, M. D., Gorbunova, V. A., Gore, M. E., Rusakov, I. G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61613-9 · Cited by 1,840
Self-citationNivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Choueiri, T. K., Powles, T., Burotto, M., Escudier, B., Bourlon, M. T., Zurawski, B., Oyervides Juárez, V. M., Hsieh, J. J., Basso, U., Shah, A. Y., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2026982 · Cited by 1,791
Self-citationLenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Motzer, R., Alekseev, B., Rha, S.-Y., Porta, C., Eto, M., Powles, T., Grünwald, V., Hutson, T. E., Kopyltsov, E., Méndez-Vidal, M. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035716 · Cited by 1,766
Self-citationMotzer, R. J., Michaelson, M. D., Redman, B. G., Hudes, G. R., Wilding, G., Figlin, R. A., Ginsberg, M. S., Kim, S. T., Baum, C. M., DePrimo, S. E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2574 · Cited by 1,634
Self-citationPathology and genetics of tumours of the urinary system and male genital organs
Eble, J. N. (2004) · International Agency for Research on Cancer eBooks · Cited by 1,596
Motzer, R. J., Bacik, J., Murphy, B. A., Russo, P., & Mazumdar, M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.289 · Cited by 1,576
Self-citationHenry, D. H., Costa, L., Goldwasser, F., Hirsh, V., Hungria, V., Prausova, J., Scagliotti, G. V., Sleeboom, H., Spencer, A., Vadhan-Raj, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.3304 · Cited by 1,263
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
Choueiri, T. K., Escudier, B., Powles, T., Mainwaring, P. N., Rini, B. I., Donskov, F., Hammers, H., Hutson, T. E., Lee, J.-L., Peltola, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510016 · Cited by 1,239
Self-citationSunitinib in Patients With Metastatic Renal Cell Carcinoma
Motzer, R. J., Rini, B. I., Bukowski, R. M., Curti, B. D., George, D. J., Hudes, G. R., Redman, B. G., Margolin, K. A., Merchan, J. R., Wilding, G., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2516 · Cited by 1,230
Self-citationFaivre, S., Delbaldo, C., Vera, K., Robert, C., Lozahic, S., Lassau, N., Bello, C., Deprimo, S., Brega, N., Massimini, G., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2194 · Cited by 1,164
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2010) · Cancer · doi:10.1002/cncr.25219 · Cited by 1,139
Self-citationEscudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Staehler, M., Negrier, S., Chevreau, C., Desai, A. A., Rolland, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.5511 · Cited by 1,085
Self-citationHeng, D. Y., Xie, W., Regan, M. M., Harshman, L. C., Bjarnason, G. A., Vaishampayan, U. N., Mackenzie, M., Wood, L., Donskov, F., Tan, M.-H., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70559-4 · Cited by 1,030
Self-citationChoueiri, T. K., Escudier, B., Powles, T., Tannir, N. M., Mainwaring, P. N., Rini, B. I., Hammers, H. J., Donskov, F., Roth, B. J., Peltola, K., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30107-3 · Cited by 958
Self-citationSunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma
Méjean, A., Ravaud, A., Thezenas, S., Colas, S., Beauval, J.-B., Bensalah, K., Geoffrois, L., Thiery-Vuillemin, A., Cormier, L., Lang, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1803675 · Cited by 946
Motzer, R. J., Hutson, T. E., Glen, H., Michaelson, M. D., Molina, A., Eisen, T., Jassem, J., Zolnierek, J., Maroto, J. P., Mellado, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00290-9 · Cited by 945
Self-citationSunitinib: From Rational Design to Clinical Efficacy
Chow, L. Q. M., & Eckhardt, S. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3602 · Cited by 883
Strumberg, D., Richly, H., Hilger, R. A., Schleucher, N., Korfee, S., Tewes, M., Faghih, M., Brendel, E., Voliotis, D., Haase, C. G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.124 · Cited by 872
McDermott, D. F., Regan, M. M., Clark, J. I., Flaherty, L. E., Weiss, G. R., Logan, T. F., Kirkwood, J. M., Gordon, M. S., Sosman, J. A., Ernstoff, M. S., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.206 · Cited by 820
Self-citationRandomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer
Yang, J. C., Sherry, R. M., Steinberg, S. M., Topalian, S. L., Schwartzentruber, D. J., Hwu, P., Seipp, C. A., Rogers-Freezer, L., Morton, K. E., White, D. E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.122 · Cited by 790
Powles, T., Plimack, E. R., Soulières, D., Waddell, T., Stus, V., Gafanov, R., Nosov, D., Pouliot, F., Melichar, B., Vynnychenko, I., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30436-8 · Cited by 751
Self-citationRosenberg, S. A., Mulé, J. J., Spiess, P. J., Reichert, C. M., & Schwarz, S. L. (1985) · The Journal of experimental medicine · doi:10.1084/jem.161.5.1169 · Cited by 745
Motzer, R. J., Escudier, B., Tomczak, P., Hutson, T. E., Michaelson, M. D., Negrier, S., Oudard, S., Gore, M. E., Tarazi, J., Hariharan, S., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70093-7 · Cited by 745
Self-citationChoueiri, T. K., Halabi, S., Sanford, B. L., Hahn, O., Michaelson, M. D., Walsh, M. K., Feldman, D. R., Olencki, T., Picus, J., Small, E. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7398 · Cited by 720
Self-citationRosen, L. S., Gordon, D., Tchekmedyian, N. S., Yanagihara, R., Hirsh, V., Krzakowski, M., Pawlicki, M., de Souza, P., Zheng, M., Urbanowitz, G., et al. (2004) · Cancer · doi:10.1002/cncr.20308 · Cited by 705
Distribution of metastatic sites in renal cell carcinoma: a population-based analysis
Bianchi, M., Sun, M., Jeldres, C., Shariat, S. F., Trinh, Q.-D., Briganti, A., Tian, Z., Schmitges, J., Graefen, M., Perrotte, P., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr362 · Cited by 653
Mekhail, T. M., Abou-Jawde, R. M., BouMerhi, G., Malhi, S., Wood, L., Elson, P., & Bukowski, R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.179 · Cited by 559
Hammers, H. J., Plimack, E. R., Infante, J. R., Rini, B. I., McDermott, D. F., Lewis, L. D., Voss, M. H., Sharma, P., Pal, S. K., Razak, A. R. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1985 · Cited by 505
Self-citationMoch, H., Gasser, T., Amin, M. B., Torhorst, J., Sauter, G., & Mihatsch, M. J. (2000) · Cancer · doi:10.1002/1097-0142(20000801)89:3<604::aid-cncr16>3.0.co;2-q · Cited by 478
Choueiri, T. K., Motzer, R. J., Rini, B. I., Haanen, J., Campbell, M. T., Venugopal, B., Kollmannsberger, C., Gravis-Mescam, G., Uemura, M., Lee, J. L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.010 · Cited by 455
Self-citationHistological Subtype is an Independent Predictor of Outcome for Patients With Renal Cell Carcinoma
Leibovich, B. C., Lohse, C. M., Crispen, P. L., Boorjian, S. A., Thompson, R. H., Blute, M. L., & Cheville, J. C. (2010) · The Journal of Urology · doi:10.1016/j.juro.2009.12.035 · Cited by 454
Sternberg, C. N., Hawkins, R. E., Wagstaff, J., Salman, P., Mardiak, J., Barrios, C. H., Zarba, J. J., Gladkov, O. A., Lee, E., Szczylik, C., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.010 · Cited by 442
Armstrong, A. J., Halabi, S., Eisen, T., Broderick, S., Stadler, W. M., Jones, R. J., Garcia, J. A., Vaishampayan, U. N., Picus, J., Hawkins, R. E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00515-x · Cited by 426
Hutson, T. E., Lesovoy, V., Al-Shukri, S., Stus, V. P., Lipatov, O. N., Bair, A. H., Rosbrook, B., Chen, C., Kim, S., & Vogelzang, N. J. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70465-0 · Cited by 404
Hutson, T. E., Escudier, B., Esteban, E., Bjarnason, G. A., Lim, H. Y., Pittman, K. B., Senico, P., Niethammer, A., Lu, D. R., Hariharan, S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.3961 · Cited by 404
Self-citationTannir, N. M., Jonasch, E., Albiges, L., Altinmakas, E., Ng, C. S., Matin, S. F., Wang, X., Qiao, W., Dubauskas Lim, Z., Tamboli, P., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.10.049 · Cited by 364
Self-citationMenko, F. H., Maher, E. R., Schmidt, L. S., Middelton, L. A., Aittomäki, K., Tomlinson, I., Richard, S., & Linehan, W. M. (2014) · Familial Cancer · doi:10.1007/s10689-014-9735-2 · Cited by 356
Clark, J. W., Eder, J. P., Ryan, D., Lathia, C., & Lenz, H.-J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2658 · Cited by 342
Awada, A., Hendlisz, A., Gil, T., Bartholomeus, S., Mano, M., de Valeriola, D., Strumberg, D., Brendel, E., Haase, C. G., Schwartz, B., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602584 · Cited by 339
Moore, M., Hirte, H. W., Siu, L., Oza, A., Hotte, S. J., Petrenciuc, O., Cihon, F., Lathia, C., & Schwartz, B. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi310 · Cited by 305
McDermott, D. F., Lee, J.-L., Ziobro, M., Suarez, C., Langiewicz, P., Matveev, V. B., Wiechno, P., Gafanov, R. A., Tomczak, P., Pouliot, F., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02365 · Cited by 291
Pal, S. K., Tangen, C., Thompson, I. M., Balzer-Haas, N., George, D. J., Heng, D. Y. C., Shuch, B., Stein, M., Tretiakova, M., Humphrey, P., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00152-5 · Cited by 287
Self-citationSengupta, S., Lohse, C. M., Leibovich, B. C., Frank, I., Thompson, R. H., Webster, W. S., Zincke, H., Blute, M. L., Cheville, J. C., & Kwon, E. D. (2005) · Cancer · doi:10.1002/cncr.21206 · Cited by 285
Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib
Motzer, R. J., Hutson, T. E., McCann, L., Deen, K., & Choueiri, T. K. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1400731 · Cited by 271
Self-citationRini, B. I., Pal, S. K., Escudier, B. J., Atkins, M. B., Hutson, T. E., Porta, C., Verzoni, E., Needle, M. N., & McDermott, D. F. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30735-1 · Cited by 261
Dutcher, J. P., de Souza, P., McDermott, D., Figlin, R. A., Berkenblit, A., Thiele, A., Krygowski, M., Strahs, A., Feingold, J., & Hudes, G. (2009) · Medical Oncology · doi:10.1007/s12032-009-9177-0 · Cited by 257
Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial
Rini, B. I., Dorff, T. B., Elson, P., Rodriguez, C. S., Shepard, D., Wood, L., Humbert, J., Pyle, L., Wong, Y.-N., Finke, J. H., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30196-6 · Cited by 257
Self-citationEscudier, B., Sharma, P., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.02.010 · Cited by 256
Self-citationChoyke, P. L., Glenn, G. M., Walther, M. M., Zbar, B., & Linehan, W. M. (2003) · Radiology · doi:10.1148/radiol.2261011296 · Cited by 246
Lipton, A., Zheng, M., & Seaman, J. (2003) · Cancer · doi:10.1002/cncr.11571 · Cited by 223
FRANK, I., BLUTE, M. L., LEIBOVICH, B. C., CHEVILLE, J. C., LOHSE, C. M., & ZINCKE, H. (2005) · Journal of Urology · doi:10.1097/01.ju.0000158043.94525.d6 · Cited by 220
Uncommon and recently described renal carcinomas
Srigley, J. R., & Delahunt, B. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.70 · Cited by 209
The skeletal metastatic complications of renal cell carcinoma
Zekri, J., Ahmed, N., Coleman, R., & Hancock, B. (2001) · International Journal of Oncology · doi:10.3892/ijo.19.2.379 · Cited by 204
Oudard, S., Banu, E., Vieillefond, A., Fournier, L., Priou, F., Medioni, J., Banu, A., Duclos, B., Rolland, F., Escudier, B., et al. (2007) · Journal of Urology · doi:10.1016/j.juro.2007.01.063 · Cited by 201
Sequential therapy with sorafenib and sunitinib in renal cell carcinoma
Dudek, A. Z., Zolnierek, J., Dham, A., Lindgren, B. R., & Szczylik, C. (2009) · Cancer · doi:10.1002/cncr.24009 · Cited by 188
Lee, C.-H., Shah, A. Y., Rasco, D., Rao, A., Taylor, M. H., Di Simone, C., Hsieh, J. J., Pinto, A., Shaffer, D. R., Girones Sarrio, R., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00241-2 · Cited by 187
Self-citationClinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
Koshkin, V. S., Barata, P. C., Zhang, T., George, D. J., Atkins, M. B., Kelly, W. J., Vogelzang, N. J., Pal, S. K., Hsu, J., Appleman, L. J., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0319-9 · Cited by 185
Lam, J. S., Shvarts, O., Said, J. W., Pantuck, A. J., Seligson, D. B., Aldridge, M. E., Bui, M. H. T., Liu, X., Horvath, S., Figlin, R. A., et al. (2005) · Cancer · doi:10.1002/cncr.21127 · Cited by 173
Renal cell cancer histological subtype distribution differs by race and sex
Lipworth, L., Morgans, A. K., Edwards, T. L., Barocas, D. A., Chang, S. S., Herrell, S. D., Penson, D. F., Resnick, M. J., Smith, J. A., & Clark, P. E. (2016) · BJU International · doi:10.1111/bju.12950 · Cited by 166
Siva, S., Louie, A. V., Warner, A., Muacevic, A., Gandhidasan, S., Ponsky, L., Ellis, R., Kaplan, I., Mahadevan, A., Chu, W., et al. (2018) · Cancer · doi:10.1002/cncr.31156 · Cited by 162
Self-citationGenetic predisposition to kidney cancer
Schmidt, L. S., & Linehan, W. M. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.09.001 · Cited by 160
Sequential Sorafenib and Sunitinib for Renal Cell Carcinoma
Sablin, M., Négrier, S., Ravaud, A., Oudard, S. M., Balleyguier, C., Gautier, J., Celier, C., Médioni, J., & Escudier, B. J. (2009) · The Journal of Urology · doi:10.1016/j.juro.2009.02.119 · Cited by 152
Zisman, A., Pantuck, A. J., Chao, D. H., DOREY, F. J., SAID, J. W., Gitlitz, B. J., deKernion, J. B., Figlin, R. A., & Belldegrun, A. S. (2001) · The Journal of Urology · doi:10.1016/s0022-5347(05)66075-2 · Cited by 151
Apolo, A. B., Nadal, R., Girardi, D. M., Niglio, S. A., Ley, L., Cordes, L. M., Steinberg, S. M., Ortiz, O. S., Cadena, J., Diaz, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01652 · Cited by 143
Self-citationThe Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma
McKay, R. R., Bossé, D., Xie, W., Wankowicz, S. A. M., Flaifel, A., Moreira, R. B., Lalani, A. A., Martini, D. J., Wei, X. X., Braun, D. A., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0475 · Cited by 130
Self-citationMotzer, R. J., Hutson, T. E., Ren, M., Dutcus, C. E., & Larkin, J. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00543-4 · Cited by 124
Self-citationMsaouel, P., Hong, A. L., Mullen, E. A., Atkins, M. B., Walker, C. L., Lee, C., Carden, M. A., Genovese, G., Linehan, W. M., Rao, P., et al. (2018) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.09.005 · Cited by 106
Renal medullary carcinoma: report of seven cases from Brazil
Watanabe, I. C., Billis, A., Guimarães, M. S., Alvarenga, M., de Matos, A. C., Cardinalli, I. A., Filippi, R. Z., de Castro, M. G., & Suzigan, S. (2007) · Modern Pathology · doi:10.1038/modpathol.3800934 · Cited by 104
Cytoreductive Nephrectomy — Patient Selection Is Key
Motzer, R. J., & Russo, P. (2018) · New England Journal of Medicine · doi:10.1056/nejme1806331 · Cited by 103
Self-citationEichelberg, C., Heuer, R., Chun, F. K. ‐., Hinrichs, K., Zacharias, M., Huland, H., & Hans Heinzer, A. (2008) · European Urology · doi:10.1016/j.eururo.2008.07.051 · Cited by 100
Prognostic Relevance of Tumour Size in T3a Renal Cell Carcinoma: A Multicentre Experience
Lam, J. S., Klatte, T., Patard, J., Goel, R. H., Guillé, F., Lobel, B., Abbou, C.-C. C., TAILLE, A. D. L., Tostain, J., Cindolo, L., et al. (2007) · European Urology · doi:10.1016/j.eururo.2007.01.106 · Cited by 100
Dall’Oglio, M. F., Ribeiro‐Filho, L. A., Antunes, A. A., Crippa, A., Nesrallah, L., Gonçalves, P. D., Leite, K. R. M., & Srougi, M. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.03.128 · Cited by 95
Escudier, B. J., Molinié, V., Sergio Bracarda, A., Maroto, P., Szczylik, C. A., Nathan, P., Négrier, S., Weiß, C., Porta, C., Grünwald, V., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.08.004 · Cited by 95
Srinivasan, R., Gurram, S., Harthy, M. A., Singer, E. A., Sidana, A., Shuch, B. M., Ball, M. W., Friend, J. C., Mac, L. M., Purcell, E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.5004 · Cited by 94
Self-citationFicarra, V., Schips, L., Guillé, F., Li, G., TAILLE, A. D. L., Galetti, T. P., Cindolo, L., Novara, G., Zigeuner, R. E., Bratti, E., et al. (2005) · Cancer · doi:10.1002/cncr.21254 · Cited by 93
Hutson, T. E., Michaelson, M. D., Kuzel, T. M., Agarwal, N., Molina, A. M., Hsieh, J. J.-D., Vaishampayan, U. N., Xie, R., Bapat, U., Ye, W., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.03.015 · Cited by 93
Self-citationVoss, M. H., Molina, A. M., Chen, Y., Woo, K. M., Chaim, J. L., Coskey, D. T., Redzematovic, A., Wang, P., Lee, W., Selçuklu, S. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.9084 · Cited by 91
Self-citationMeyer, E., Pasquier, D., Bernadou, G., Calais, G., Maroun, P., Bossi, A., Théodore, C., Albiges, L. K., Stefan, D., de Crevoisier, R., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.04.008 · Cited by 82
Siva, S., Ellis, R. J., Ponsky, L. E., Teh, B. S., Mahadevan, A., Muacevic, A., Staehler, M. D., Onishi, H., Wersäll, P. J., Nomiya, T., et al. (2016) · Future Oncology · doi:10.2217/fon.16.2 · Cited by 79
Self-citationMotzer, R. J., Escudier, B. J., Powles, T. B., Scheffold, C., & Choueiri, T. K. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0061-6 · Cited by 75
Self-citationMinervini, A., Lilas, L., Minervini, R., & Selli, C. (2002) · Cancer · doi:10.1002/cncr.10510 · Cited by 74
Prognostic Impact of Tumor Size on pT2 Renal Cell Carcinoma: An International Multicenter Experience
Klatte, T., Patard, J., Goel, R. H., Kleid, M. D., Guillé, F., Lobel, B., Abbou, C.-C. C., TAILLE, A. D. L., Tostain, J., Cindolo, L., et al. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.03.046 · Cited by 67
Microvascular tumour invasion in renal cell carcinoma: the most important prognostic factor
Dall’Oglio, M. F., Antunes, A. A., Sarkis, A. S., Crippa, A., Leite, K. R. M., Lucón, A. M., & Srougi, M. (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.07015.x · Cited by 66
Amzal, B., Fu, S., Meng, J., Lister, J., & Karcher, H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184423 · Cited by 60
Hunter, G. K., Balagamwala, E. H., Koyfman, S. A., Bledsoe, T. B., Sheplan, L. J., Reddy, C. A., Chao, S. T., Djemil, T., Angelov, L., & Videtic, G. M. M. (2012) · Practical Radiation Oncology · doi:10.1016/j.prro.2012.01.005 · Cited by 55
Buti, S., Bersanelli, M., Maines, F., Facchini, G., Gelsomino, F., Zustovich, F., Santoni, M., Verri, E., Giorgi, U. D., Masini, C., et al. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.12.024 · Cited by 55
de Velasco, G., McKay, R. R., Lin, X., Moreira, R. B., Simantov, R., & Choueiri, T. K. (2017) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2017.03.004 · Cited by 49
Self-citationCiccarese, C., Iacovelli, R., Brunelli, M., Massari, F., Bimbatti, D., Fantinel, E., MARCO, V. D., Porcaro, A. B., Martignoni, G., Artibani, W., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.030 · Cited by 43
Metastatic renal cell carcinoma: Results of a population-based study with 25 years follow-up
Schlesinger‐Raab, A., Treiber, U., Zaak, D., Hölzel, D., & Engel, J. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.07.039 · Cited by 40
Park, I., Lee, S., & Lee, J. (2018) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.05.011 · Cited by 40
FDA approves pembrolizumab plus axitinib for advanced renal cell carcinoma
(2019) · Case Medical Research · doi:10.31525/cmr-14804d4 · Cited by 19
Cited by
Renal Cell Carcinoma: A Review
Rose, T. L., & Kim, W. Y. (2024) · JAMA · doi:10.1001/jama.2024.12848 · Cited by 374
Ebrahimi, H., Dizman, N., Meza, L., Malhotra, J., Li, X., Dorff, T., Frankel, P., Llamas-Quitiquit, M., Hsu, J., Zengin, Z. B., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03086-4 · Cited by 109
Models of renal cell carcinoma used to investigate molecular mechanisms and develop new therapeutics
Shapiro, D. D., Virumbrales-Muñoz, M., Beebe, D. J., & Abel, E. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.871252 · Cited by 28
Revisiting mechanisms of resistance to immunotherapies in metastatic clear-cell renal-cell carcinoma
Chatwal, M. S., Chahoud, J., & Spiess, P. E. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.09 · Cited by 12
Metadata
- Authors
- Motzer, R. J., Jonasch, E., Agarwal, N., Alva, A., Baine, M., Beckermann, K., Carlo, M. I., Choueiri, T. K., Costello, B. A., Derweesh, I. H., Desai, A., Ged, Y., George, S., Gore, J. L., Haas, N., Hancock, S. L., Kapur, P., Kyriakopoulos, C., Lam, E. T., Lara, P. N., Lau, C., Lewis, B., Madoff, D. C., Manley, B., Michaelson, M. D., Mortazavi, A., Nandagopal, L., Plimack, E. R., Ponsky, L., Ramalingam, S., Shuch, B., Smith, Z. L., Sosman, J., Dwyer, M. A., Gurski, L. A., & Motter, A.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2022-01
- Volume
- 20
- Issue
- 1
- Pages
- 71-90
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W4205710681
- Cited by
- 667
- References
- 106
- FWCI
- 84.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.